SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Moleculin Biotech, Inc.
Date: Jan. 2, 2026 · CIK: 0001659617 · Accession: 0000000000-26-000020

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-292420

Date
January 2, 2026
Author
Division of
Form
UPLOAD
Company
Moleculin Biotech, Inc.

Letter

Re: Moleculin Biotech, Inc. Registration Statement on Form S-3 Filed December 23, 2025 File No. 333-292420 Dear Walter V. Klemp:

January 2, 2026

Walter V. Klemp Chief Executive Officer Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, TX 77007

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Cavas S. Pavri

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 January 2, 2026

Walter V. Klemp
Chief Executive Officer
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007

 Re: Moleculin Biotech, Inc.
 Registration Statement on Form S-3
 Filed December 23, 2025
 File No. 333-292420
Dear Walter V. Klemp:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Chris Edwards at 202-551-6761 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Cavas S. Pavri
</TEXT>
</DOCUMENT>